Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1014 | 2018 |
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients S Jarius, K Ruprecht, B Wildemann, T Kuempfel, M Ringelstein, C Geis, ... Journal of neuroinflammation 9, 1-17, 2012 | 846 | 2012 |
Transferrin receptor internalization sequence YXRF implicates a tight turn as the structural recognition motif for endocytosis JF Collawn, M Stangel, LA Kuhn, V Esekogwu, S Jing, IS Trowbridge, ... Cell 63 (5), 1061-1072, 1990 | 675 | 1990 |
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 620 | 2017 |
Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses I Kleiter, A Gahlen, N Borisow, K Fischer, KD Wernecke, B Wegner, ... Annals of neurology 79 (2), 206-216, 2016 | 412 | 2016 |
Glial response during cuprizone-induced de-and remyelination in the CNS: lessons learned V Gudi, S Gingele, T Skripuletz, M Stangel Frontiers in cellular neuroscience 8, 73, 2014 | 407 | 2014 |
Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination T Skripuletz, D Hackstette, K Bauer, V Gudi, R Pul, E Voss, K Berger, ... Brain 136 (1), 147-167, 2013 | 397 | 2013 |
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent T Skripuletz, M Lindner, A Kotsiari, N Garde, J Fokuhl, F Linsmeier, ... The American journal of pathology 172 (4), 1053-1061, 2008 | 310 | 2008 |
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial IN van Schaik, V Bril, N van Geloven, HP Hartung, RA Lewis, G Sobue, ... The Lancet Neurology 17 (1), 35-46, 2018 | 277 | 2018 |
Regional differences between grey and white matter in cuprizone induced demyelination V Gudi, D Moharregh-Khiabani, T Skripuletz, PN Koutsoudaki, A Kotsiari, ... Brain research 1283, 127-138, 2009 | 270 | 2009 |
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis M Stangel, S Fredrikson, E Meinl, A Petzold, O Stüve, H Tumani Nature Reviews Neurology 9 (5), 267-276, 2013 | 261 | 2013 |
De-and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. T Skripuletz, V Gudi, D Hackstette, M Stangel Histology and histopathology 26 (12), 1585-1597, 2011 | 246 | 2011 |
Characterisation of microglia during de-and remyelination: can they create a repair promoting environment? EV Voß, J Škuljec, V Gudi, T Skripuletz, R Pul, C Trebst, M Stangel Neurobiology of disease 45 (1), 519-528, 2012 | 224 | 2012 |
Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions I Kleiter, A Gahlen, N Borisow, K Fischer, KD Wernecke, K Hellwig, ... Neurology: Neuroimmunology & Neuroinflammation 5 (6), e504, 2018 | 209 | 2018 |
Towards the implementation of ‘no evidence of disease activity’in multiple sclerosis treatment: the multiple sclerosis decision model M Stangel, IK Penner, BA Kallmann, C Lukas, BC Kieseier Therapeutic advances in neurological disorders 8 (1), 3-13, 2015 | 208 | 2015 |
Remyelinating strategies for the treatment of multiple sclerosis M Stangel, HP Hartung Progress in neurobiology 68 (5), 361-376, 2002 | 194 | 2002 |
Longitudinal extensive transverse myelitis—it's not all neuromyelitis optica C Trebst, P Raab, EV Voss, P Rommer, M Abu-Mugheisib, UK Zettl, ... Nature Reviews Neurology 7 (12), 688-698, 2011 | 193 | 2011 |
Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination M Lindner, S Heine, K Haastert, N Garde, J Fokuhl, F Linsmeier, C Grothe, ... Neuropathology and applied neurobiology 34 (1), 105-114, 2008 | 190 | 2008 |
Fumaric acid and its esters: an emerging treatment for multiple sclerosis D Moharregh-Khiabani, RA Linker, R Gold, M Stangel Current neuropharmacology 7 (1), 60-64, 2009 | 181 | 2009 |
Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action R Gold, RA Linker, M Stangel Clinical Immunology 142 (1), 44-48, 2012 | 178 | 2012 |